- Home
- EQ vs KBSX Comparison
EQ vs KBSX Comparison
Compare EQ & KBSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- KBSX
- Stock Information
- Founded
- EQ 2017
- KBSX 1976
- Country
- EQ United States
- KBSX Taiwan
- Employees
- EQ N/A
- KBSX N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- KBSX Recreational Games/Products/Toys
- Sector
- EQ Health Care
- KBSX Consumer Discretionary
- Exchange
- EQ Nasdaq
- KBSX Nasdaq
- Market Cap
- EQ 85.1M
- KBSX 75.7M
- IPO Year
- EQ 2018
- KBSX N/A
- Fundamental
- Price
- EQ $1.34
- KBSX $1.69
- Analyst Decision
- EQ Hold
- KBSX
- Analyst Count
- EQ 2
- KBSX 0
- Target Price
- EQ $1.00
- KBSX N/A
- AVG Volume (30 Days)
- EQ 725.3K
- KBSX 26.3K
- Earning Date
- EQ 11-12-2025
- KBSX 08-21-2025
- Dividend Yield
- EQ N/A
- KBSX N/A
- EPS Growth
- EQ N/A
- KBSX N/A
- EPS
- EQ N/A
- KBSX N/A
- Revenue
- EQ $16,553,000.00
- KBSX $40,863,331.00
- Revenue This Year
- EQ N/A
- KBSX N/A
- Revenue Next Year
- EQ N/A
- KBSX N/A
- P/E Ratio
- EQ N/A
- KBSX N/A
- Revenue Growth
- EQ N/A
- KBSX 20.42
- 52 Week Low
- EQ $0.27
- KBSX $1.26
- 52 Week High
- EQ $2.35
- KBSX $15.48
- Technical
- Relative Strength Index (RSI)
- EQ 43.10
- KBSX 62.96
- Support Level
- EQ $1.41
- KBSX $1.45
- Resistance Level
- EQ $1.64
- KBSX $1.53
- Average True Range (ATR)
- EQ 0.11
- KBSX 0.07
- MACD
- EQ -0.02
- KBSX 0.02
- Stochastic Oscillator
- EQ 9.11
- KBSX 83.33
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
About KBSX FST Corp. Ordinary Shares
FST Corp is a renowned manufacturer and innovator in the golf industry with a growing portfolio of creative golf products, including acclaimed golf club shafts and other equipment. The Company has engaged in the research, development, manufacturing, and sales of golf club shafts. The Company currently produces and sells golf club shafts under the Company's own high performance KBS golf club shaft brand, and serves as an original equipment manufacturer (OEM) and original design manufacturer (ODM) for other world-renowned golf equipment brands, golf equipment OEMs, and golf equipment distributors that provide consumers with customized golf club services.